A phase I, single-centre, open-label, fixed-dose study of the safety and efficacy of up- to three-days application of 0.05% PEP005 [ingenol mebutate] topical gel in the treatment of patients with common wart(s) (Verruca[e] vulgaris) on the dorsal hand
Withdrawn prior to enrolment
Phase of Trial: Phase I
Latest Information Update: 12 Feb 2016
At a glance
- Drugs Ingenol mebutate (Primary)
- Indications Warts
- Focus Adverse reactions
- 14 Feb 2008 Status changed from recruiting to withdrawn prior to recruitment.
- 04 Nov 2007 New trial record.